EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Peri-procedural Lidocaine Administration for Radiofrequency Ablation of Hepatocellular Carcinoma: A Pilot Study

Sergiu Sargarovschi, Zeno Adrian Sparchez, Alexandru Leonard Alexa, Andreea Paunescu, Ioana Rucsanda, Dan Valean, Andreea Benea, Daniela Ionescu

Journal of Gastrointestinal and Liver Diseases · 2026

DOI: 10.15403/jgld-7414 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2026. Verfasst von Sergiu Sargarovschi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca; Research Association in Anesthesia and Intensive Care (ACATI), Cluj-Napoca; Prof. D…. Hauptthemen laut MEDLINE: Lidocaine, Liver Neoplasms, Carcinoma, Hepatocellular, Radiofrequency Ablation. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Radiofrequency ablation (RFA) is a curative option for early-stage hepatocellular carcinoma (HCC) when liver resection or transplantation is not a suitable option. This study evaluated whether a peri-procedural intravenous lidocaine infusion could reduce neutrophil extracellular trap formation (NETosis), neutrophil-to-lymphocyte ratio (NLR) and improve 1-year outcomes after RFA.

Methods

In this single-centre, randomized trial, 50 adult HCC patients undergoing RFA were allocated 1:1 to receive propofol-fentanyl sedation alone (PF group, n=25) or combined with intravenous lidocaine (1.5 mg/kg bolus, then 1 mg/kg/h for 24 hours; PF-L group, n=25). Serum citrullinated histone H3 (H3Cit), NLR, and C-reactive protein (CRP) were assessed at baseline and 24 hours post-ablation. The primary endpoint was the change in H3Cit expression. Secondary endpoints included changes in NLR and C-reactive protein (CRP), as well as 1-year overall mortality, disease-free survival, and local recurrence rates.

Results

24 patients in PF-L group and 25 patients in PF group completed the study. Intra-group H3Cit levels significantly decreased from baseline at 24 hours only in the PF-L group (p=0.031). However, the between-group difference in H3Cit variation levels was not significant (p=0.352). Postoperative NLR changes were also comparable between groups (p=0.354). The overall 1-year mortality rate was 12%, with no significant variance between the two arms.

Conclusions

Adding intravenous lidocaine to sedation resulted in an intra-group reduction in H3Cit expression following RFA but did not produce a statistically significant reduction compared to standard propofol-fentanyl sedation alone. 1-year survival and local recurrence rates did not differ between groups. However, our preliminary findings justify the need for larger, baseline-balanced trials to evaluate periprocedural NETosis modulation by sedation regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LidocaineLiver NeoplasmsCarcinoma, HepatocellularRadiofrequency AblationAnesthetics, LocalHumansPilot ProjectsFemaleMiddle AgedMaleAgedTreatment OutcomeTime FactorsNeutrophilsInfusions, IntravenousC-Reactive ProteinPropofolFentanylLymphocytesNeoplasm Recurrence, Local

Substanzen

LidocaineAnesthetics, LocalC-Reactive ProteinPropofolFentanyl

Autor:innen und Institutionen

  • Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca; Research Association in Anesthesia and Intensive Care (ACATI), Cluj-Napoca; Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatolog…
  • Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca; Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Cluj-Napoca, Romania. zsparchez@gmail.com.
  • The OncoGen Association, Timisoara, Romania. andreea.paunescu@ymail.com.
  • Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Cluj-Napoca, Romania. ioanarucsanda@yahoo.com.
  • Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. valeand92@gmail.com.
  • Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Cluj-Napoca, Romania. andreeabenea79@yahoo.com.

Zitieren

APA

Sargarovschi, S., Sparchez, Z. A., Alexa, A. L., Paunescu, A., Rucsanda, I., Valean, D., Benea, A., & Ionescu, D. (2026). Peri-procedural Lidocaine Administration for Radiofrequency Ablation of Hepatocellular Carcinoma: A Pilot Study. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-7414

Vancouver

Sargarovschi S, Sparchez ZA, Alexa AL, Paunescu A, Rucsanda I, Valean D, et al. Peri-procedural Lidocaine Administration for Radiofrequency Ablation of Hepatocellular Carcinoma: A Pilot Study. Journal of Gastrointestinal and Liver Diseases. 2026. doi:10.15403/jgld-7414

BibTeX
@article{Sargarovschi2026,
  author = {Sargarovschi, Sergiu and Sparchez, Zeno Adrian and Alexa, Alexandru Leonard and Paunescu, Andreea and Rucsanda, Ioana and Valean, Dan and Benea, Andreea and Ionescu, Daniela},
  title = {Peri-procedural Lidocaine Administration for Radiofrequency Ablation of Hepatocellular Carcinoma: A Pilot Study},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2026},
  doi = {10.15403/jgld-7414}
}
Kostenlos starten →